ORTHO TRI-CYCLEN 21

Clinical safety rating: caution

Comprehensive clinical and safety monograph for ORTHO TRI-CYCLEN 21 (ORTHO TRI-CYCLEN 21).

How it works

Combination estrogen-progestin oral contraceptive; suppresses gonadotropin secretion (FSH, LH) via negative feedback, preventing ovulation; increases cervical mucus viscosity and alters endometrial receptivity.

What the body does with it

Metabolism	Norgestimate: hydrolyzed to norelgestromin and norgestrel; metabolized by CYP3A4, CYP2C9, and CYP2C19. Ethinyl estradiol: metabolized by CYP3A4 and undergoes glucuronidation.
Excretion	Renal: ~70% (metabolites, primarily glucuronide and sulfate conjugates of norgestimate and ethinyl estradiol); Fecal: ~30% (biliary elimination of unchanged drug and metabolites).
Half-life	Norgestimate: ~24 hours (terminal); ethinyl estradiol: ~17 hours (terminal). Steady-state achieved within 5-7 days; clinical significance: missed doses may increase contraceptive failure risk.
Protein binding	Norgestimate: ~99% bound to albumin and SHBG; ethinyl estradiol: ~98% bound to albumin; norethindrone (active metabolite) binds with similar high affinity.
Volume of Distribution	Norgestimate: Vd ~6-8 L/kg; ethinyl estradiol: Vd ~3-5 L/kg. Large Vd indicates extensive tissue distribution including breast, uterine, and hepatic tissues; clinical relevance: potential for drug interactions (e.g., enzyme inducers).
Bioavailability	Oral: Norgestimate ~75% (first-pass metabolism limits bioavailability); ethinyl estradiol ~40-60% (substantial first-pass effect).
Onset of Action	Oral: ~7 days of consistent dosing for full contraceptive effect (ovulation suppression); immediate if therapy started on first day of menstrual cycle.
Duration of Action	Oral: 24 hours; requires daily dosing; suppression of ovulation maintained if taken without interruption. Missed pills >12 hours reduce efficacy.

Classification & Brands

Dosing & administration

One tablet daily for 21 days, followed by 7 days of placebo, then repeat. Each tablet contains 0.180 mg norgestimate and 0.035 mg ethinyl estradiol (days 1–7), 0.215 mg/0.035 mg (days 8–14), and 0.250 mg/0.035 mg (days 15–21). Oral route.

Dosage form	TABLET
Renal impairment	No specific dose adjustment is provided in manufacturer labeling; use with caution in patients with renal impairment. GFR-based adjustments are not established.
Liver impairment	Contraindicated in patients with hepatic disease or hepatocellular carcinoma. Child-Pugh class B or C: contraindicated. Child-Pugh class A: use with caution, no specific dose adjustment defined.
Pediatric use	Safety and efficacy established in postmenarchal females; dosing is same as adult: one tablet daily for 21 days. Weight-based dosing not applicable.
Geriatric use	Not indicated for use in postmenopausal women. No specific considerations available.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for ORTHO TRI-CYCLEN 21 (ORTHO TRI-CYCLEN 21).

Breastfeeding	Contraindicated in breastfeeding due to estrogens reducing milk production and quality. Limited data; M/P ratio not established. Alternative methods preferred.
Teratogenic Risk	First trimester: Risk of congenital anomalies (limb defects, neural tube defects) based on case reports; overall risk low. Second/third trimester: Possible increased risk of intrauterine growth restriction and preterm birth. Postnatal: Potential for jaundice and transient hormonal effects in neonates.
Fetal Monitoring

Warnings & precautions

■ FDA Black Box Warning

Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptives (COCs). Women over 35 who smoke should not use COCs.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Known or suspected pregnancy","Current or history of thromboembolic disorders (e.g., DVT, PE)","Cerebrovascular or coronary artery disease","Known or suspected breast cancer or other estrogen-sensitive neoplasia","Undiagnosed abnormal genital bleeding","Hepatic adenoma or carcinoma, or active liver disease","Hypersensitivity to any component","Smoking in women over 35 years","Uncontrolled hypertension","Diabetes with vascular involvement","Migraine with aura if >35 years","Major surgery with prolonged immobilization"]

Clinical Precautions

Precautions

["Thrombotic disorders (e.g., thrombophlebitis, pulmonary embolism, stroke, myocardial infarction)","Hepatic disease (including hepatic adenoma or carcinoma)","Hypertension","Gallbladder disease","Carbohydrate/lipid metabolism disturbances","Headache (including migraine with focal symptoms)","Uterine bleeding irregularities"]

Clinical Tips & Counseling

Drug interactions

Loading safety data…

ORTHO TRI-CYCLEN 21

Clinical safety rating: caution

Comprehensive clinical and safety monograph for ORTHO TRI-CYCLEN 21 (ORTHO TRI-CYCLEN 21).

How it works

What the body does with it

Metabolism	Norgestimate: hydrolyzed to norelgestromin and norgestrel; metabolized by CYP3A4, CYP2C9, and CYP2C19. Ethinyl estradiol: metabolized by CYP3A4 and undergoes glucuronidation.
Excretion	Renal: ~70% (metabolites, primarily glucuronide and sulfate conjugates of norgestimate and ethinyl estradiol); Fecal: ~30% (biliary elimination of unchanged drug and metabolites).
Half-life	Norgestimate: ~24 hours (terminal); ethinyl estradiol: ~17 hours (terminal). Steady-state achieved within 5-7 days; clinical significance: missed doses may increase contraceptive failure risk.
Protein binding	Norgestimate: ~99% bound to albumin and SHBG; ethinyl estradiol: ~98% bound to albumin; norethindrone (active metabolite) binds with similar high affinity.
Volume of Distribution	Norgestimate: Vd ~6-8 L/kg; ethinyl estradiol: Vd ~3-5 L/kg. Large Vd indicates extensive tissue distribution including breast, uterine, and hepatic tissues; clinical relevance: potential for drug interactions (e.g., enzyme inducers).
Bioavailability	Oral: Norgestimate ~75% (first-pass metabolism limits bioavailability); ethinyl estradiol ~40-60% (substantial first-pass effect).
Onset of Action	Oral: ~7 days of consistent dosing for full contraceptive effect (ovulation suppression); immediate if therapy started on first day of menstrual cycle.
Duration of Action	Oral: 24 hours; requires daily dosing; suppression of ovulation maintained if taken without interruption. Missed pills >12 hours reduce efficacy.

Classification & Brands

Dosing & administration

Dosage form	TABLET
Renal impairment	No specific dose adjustment is provided in manufacturer labeling; use with caution in patients with renal impairment. GFR-based adjustments are not established.
Liver impairment	Contraindicated in patients with hepatic disease or hepatocellular carcinoma. Child-Pugh class B or C: contraindicated. Child-Pugh class A: use with caution, no specific dose adjustment defined.
Pediatric use	Safety and efficacy established in postmenarchal females; dosing is same as adult: one tablet daily for 21 days. Weight-based dosing not applicable.
Geriatric use	Not indicated for use in postmenopausal women. No specific considerations available.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for ORTHO TRI-CYCLEN 21 (ORTHO TRI-CYCLEN 21).

Breastfeeding	Contraindicated in breastfeeding due to estrogens reducing milk production and quality. Limited data; M/P ratio not established. Alternative methods preferred.
Teratogenic Risk	First trimester: Risk of congenital anomalies (limb defects, neural tube defects) based on case reports; overall risk low. Second/third trimester: Possible increased risk of intrauterine growth restriction and preterm birth. Postnatal: Potential for jaundice and transient hormonal effects in neonates.
Fetal Monitoring

Warnings & precautions

■ FDA Black Box Warning

Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptives (COCs). Women over 35 who smoke should not use COCs.